Segment Reporting (Details) $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) segment	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Segment Reporting [Abstract]
Number of Reportable Segments | segment	2
Segment Reporting Information [Line Items]
Impact of foreign currency fluctuations	$ 64	$ 149	$ 208
Net sales	16,747	14,240	12,682
Other			(60)
Cost of products sold	5,053	4,276	4,038
Selling, general and administrative expenses	4,967	4,375	3,965
Research and development expenses	1,437	1,282	1,214
Other segment items	33	43	45
Segment operating incom	5,193	4,115	3,272
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments	(8,887)	(7,553)	(7,078)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs	(1,070)	(567)	(789)
Amortization expense	(856)	(828)	(803)
Other			(60)
Operating income (loss)	2,603	2,343	1,649
Other income (expense), net	(321)	(358)	(508)
Income (loss) before income taxes	2,282	1,985	1,141
Operating Segments
Segment Reporting Information [Line Items]
Net sales of reportable segments	16,683	14,091	12,535
Operating Segments | MedSurg
Segment Reporting Information [Line Items]
Net sales of reportable segments	5,973	5,378	4,855
Net sales	5,993	5,422	4,911
Cost of products sold	$ 1,649	$ 1,470	$ 1,401
Cost of products sold, percentage of net sale	27.60%	27.30%	28.90%
Selling, general and administrative expenses	$ 1,801	$ 1,626	$ 1,510
Selling, general and administrative expenses, percentage of net sale	30.20%	30.20%	31.10%
Research and development expenses	$ 462	$ 427	$ 432
Research and development expenses, percentage of net sale	7.70%	7.90%	8.90%
Other segment items	$ 14	$ 20	$ 23
Other segment items, percentage of net sale	0.20%	0.40%	0.50%
Segment operating incom	$ 2,046	$ 1,834	$ 1,489
Segment operating income, percentage of net sale	34.30%	34.10%	30.70%
Operating Segments | Cardiovascular
Segment Reporting Information [Line Items]
Net sales of reportable segments	$ 10,711	$ 8,714	$ 7,679
Net sales	10,755	8,819	7,831
Cost of products sold	$ 3,404	$ 2,805	$ 2,637
Cost of products sold, percentage of net sale	31.80%	32.20%	34.30%
Selling, general and administrative expenses	$ 3,166	$ 2,749	$ 2,454
Selling, general and administrative expenses, percentage of net sale	29.60%	31.50%	32.00%
Research and development expenses	$ 975	$ 855	$ 782
Research and development expenses, percentage of net sale	9.10%	9.80%	10.20%
Other segment items	$ 19	$ 23	$ 22
Other segment items, percentage of net sale	0.20%	0.30%	0.30%
Segment operating incom	$ 3,147	$ 2,281	$ 1,784
Segment operating income, percentage of net sale	29.40%	26.20%	23.20%
Segment Reporting, Reconciling Item, Corporate Nonsegment
Segment Reporting Information [Line Items]
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments	$ (663)	$ (377)	$ 29